Summary Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age […]
Summary No abstract available. Countries: Estonia, Hungary, Iceland, Indonesia, Iran, Japan, Latvia, Lebanon, Lithuania, Pakistan, Romania, Saudi Arabia, Slovenia, South Korea, United Arab Emirates Read the Full Report
Summary Objective In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies. Study Design Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and […]
Summary Background & Aims Prevalence of hepatitis C virus (HCV) infection in the Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct-acting antivirals (DAAs) is tolerable and effective but expensive. Our analysis projected the future HCV-related disease burden in the Netherlands by applying different treatment scenarios. Methods Using a modelling approach, the size of […]
Summary Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity […]
Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures […]
Summary On-therapy decline or normalization of liver enzyme levels is often observed following initiation of interferon-based hepatitis C virus (HCV) antiviral treatment and may reflect response to therapy and decreasing HCV RNA levels (1,2). On-treatment alanine aminotransferase (ALT) level elevation may be associated with persistent viremia (3–5). The value of enzymatic response in predicting sustained […]
Summary Background The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden. Aim A modelling approach […]
Summary Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment […]
Summary Background This manuscript serves as an update to position papers published in 2014 based on the available Belgian hepatitis C virus (HCV) epidemiological data. Methods Building on the current standard of care (2015: 900 = F3 patients treated with 70-85% SVR), four new scenarios were developed to achieve the goals of near viral elimination […]
English 
Spanish 
French 
Russian 
Arabic